Abstract: Aspects of the present disclosure relate to systems and methods for analyzing a tumor, and more specifically, analyzing a tumor to identify a biological aggressiveness of the tumor. One example method for tumor analysis includes: receiving one or more input features associated with a geometric shape of a tumor, the one or more input features including at least a value indicating a circularity of the tumor; determining, via a machine learning component, a characteristic of the tumor based on the one or more input features, the characteristic being indicative of patient survivability; and outputting an indication of the characteristic.

Abstract: The present invention includes compositions and methods for treating an autoimmune disorder or a cancer in a subject in need thereof, the method comprising: administering an effective amount of a composition comprising an oligonucleotide that specifically binds a complementary sequence of the Interleukin-7 receptor (IL7R) pre-mRNA that influences splicing of exon 6, wherein the SM-ASO increases or decreases inclusion of exon 6 in IL7R pre-mRNAs and respectively decreases or increases expression of the soluble isoform of IL7R (sIL7R). In certain embodiments, the oligonucleotide is an antisense oligonucleotide (ASO), or a splice-modulating antisense oligonucleotide (SM-ASO).

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.

Abstract: A surgical loupes head strap is disclosed. The surgical loupes head strap may include a first monofilament and a second monofilament coupled by at least one sleeve. The surgical loupes head strap may further include a first coupler with a first hole and a second hole, where the first hole is configured to surround and couple to a first end of the first monofilament, and the second hole is configured to surround and couple to at least a portion of a first surgical loupes headgear temple. The surgical loupes head strap may further include a second coupler with a first hole and a second hole, where the first hole is configured to surround and couple to a first end of the second monofilament, and the second hole is configured to surround and couple to at least a portion of a second surgical loupes headgear temple.

Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.

Abstract: The present disclosure provides ?2?-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an ?2?-1 C-terminal domain peptide which blocks binding of ?2?-1 to the glutamate receptors NMDAR and AMPAR.

Abstract: Chronic tobacco smoke exposure (TSE)-induced lung injury includes increased alveolar and airway inflammation, type II alveolar epithelial cells (A2Cs) senescence and apoptosis, and mucus hypersecretion by airway epithelial cells (AECs) that can be treated by the caveolin-1 peptide CSP7 (SEQ ID NO:1). Caveolin-1 and p53 mediated induction of plasminogen activator inhibitor-1 (PAI-1) expression by interleukin 17A, TSE, pollution and other causes leads to lung injury, which can be abrogated by CSP7 treatment, which abolishes A2Cs senescence and apoptosis and AEC mucus hypersecretion. CSP7 treatment of lung tissue of patients with TSE-induced lung injury decreases A2C apoptosis and AEC mucus hypersecretion. Lung injury with A2Cs senescence and apoptosis and AEC mucus hypersecretion caused by TSE-induced PAI-1 expression in lung tissue of patients is abolished by CSP7.

Abstract: The current disclosure describes effective therapeutic treatments and diagnostic/prognostic methods for colorectal cancer based on the expression or activity level of biomarkers. Aspects of the disclosure relate to a method for treating a subject for colorectal cancer, the method comprising treating the subject for colorectal cancer after the expression level of one or more biomarker genes from Table 1, Table 2, Table 3, Table 4, Table 5, Table S2, Table S3, Table S4, Table S5, FIG. 4A, and/or FIG. 4B has been determined in a sample from the subject.

Abstract: The present disclosure concerns methods and compositions related to adoptive cell therapy and its efficacy related to the gut microbiome. In specific cases, it may be determined for an individual whether or not a chimeric antigen receptor (CAR) T-cell therapy will be effective for an individual based on their gut microbiome. An individual may be provided a composition comprising one or more particular microbe compositions based on analysis of the gut microbiome of the individual and prior to administration of CAR T-cell therapy, in specific embodiments.

Abstract: Compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are disclosed.

Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.

Abstract: The invention provides for novel glaucoma surgical devices comprising a microfluidic meshwork. The meshwork comprises interconnected, cellular-dimensioned microfluidic channels. Excess fluid in the eye can be drained and diffused through the microfluidic channels. The meshwork is porous and highly flexible, affording mechanical compliance similar to that of eye tissue. The meshwork minimizes foreign body reactions to the implant, decreasing fibrosis and capsule formation.

Abstract: The present disclosure provides a method of preventing, treating, or inhibiting migraine in a subject, by administering to the subject an amount of first therapeutic selected from cercosporamide, eFT508, or 4EGI-1 sufficient to prevent, treat, or inhibit said migraine. The present disclosure further provides a composition including at least two of cercosporamide. eFT508, or 4EGI-1, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject and a pharmaceutically acceptable carrier. The present disclosure further provides a composition including at least one of cercosporamide, eFT508, or 4EGI-1 and at least one additional migraine therapeutic, both in an amount sufficient to prevent, treat, or inhibit migraine in a subject, and a pharmaceutically acceptable carrier.

Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.

Abstract: Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

Abstract: The disclosure provides a flexible, narrow medical device (such as a micro-catheter or a guidewire) that is controllably moved and steered through lumens of a body. The medical device may include an electrically-actuatable bendable portion at a distal end, which may be provided by a polymer electrolyte layer, electrodes distributed about the polymer electrolyte layer, and electrical conduits coupled to the electrodes, such that the polymer electrolyte layer deforms asymmetrically in response to an electrical signal through one or more conduits. The disclosure further includes a controller for moving the device into and out of bodily lumens and for applying the electrical signal for steering the device. The device further includes methods of preparing the polymer electrolyte layer in tubular shape.

Abstract: An apparatus for a heart of a patient having a cardiac assist device adapted to be implanted into the patient to assist the heart with pumping blood. The apparatus has a sensor adapted to be implanted into the patient. The sensor in communication with the cardiac assist device and the heart which measures native volume of the heart. Alternatively, the sensor monitors the heart based on admittance while the cardiac assist device. Alternatively, the sensor monitors the heart based on impedance.

Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.

Abstract: Described herein are dry immunogenic compositions and methods of freezing aluminum-containing vaccines such that when converted into a dried powder, the dry composition can be readily administered without loss of activity. Also described are methods of intranasal administering dry immunogenic compositions comprising antigens and aluminum adjuvants.